Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy
- PMID: 22971934
- PMCID: PMC3490751
- DOI: 10.1186/2045-3701-2-32
Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy
Abstract
Human Immunodeficiency Virus Type 1 (HIV-1) protease inhibitors (PIs) are the most potent class of drugs in antiretroviral therapies. However, viral drug resistance to PIs could emerge rapidly thus reducing the effectiveness of those drugs. Of note, all current FDA-approved PIs are competitive inhibitors, i.e., inhibitors that compete with substrates for the active enzymatic site. This common inhibitory approach increases the likelihood of developing drug resistant HIV-1 strains that are resistant to many or all current PIs. Hence, new PIs that move away from the current target of the active enzymatic site are needed. Specifically, allosteric inhibitors, inhibitors that prohibit PR enzymatic activities through non-competitive binding to PR, should be sought. Another common feature of current PIs is they were all developed based on the structure-based design. Drugs derived from a structure-based strategy may generate target specific and potent inhibitors. However, this type of drug design can only target one site at a time and drugs discovered by this method are often associated with strong side effects such as cellular toxicity, limiting its number of target choices, efficacy, and applicability. In contrast, a cell-based system may provide a useful alternative strategy that can overcome many of the inherited shortcomings associated with structure-based drug designs. For example, allosteric PIs can be sought using a cell-based system without considering the site or mechanism of inhibition. In addition, a cell-based system can eliminate those PIs that have strong cytotoxic effect. Most importantly, a simple, economical, and easy-to-maintained eukaryotic cellular system such as yeast will allow us to search for potential PIs in a large-scaled high throughput screening (HTS) system, thus increasing the chances of success. Based on our many years of experience in using fission yeast as a model system to study HIV-1 Vpr, we propose the use of fission yeast as a possible surrogate system to study the effects of HIV-1 protease on cellular functions and to explore its utility as a HTS system to search for new PIs to battle HIV-1 resistant strains.
Figures
Similar articles
-
Development of A Fission Yeast Cell-Based Platform for High Throughput Screening of HIV-1 Protease Inhibitors.Curr HIV Res. 2019;17(6):429-440. doi: 10.2174/1570162X17666191128102839. Curr HIV Res. 2019. PMID: 31782368 Free PMC article.
-
Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast (Schizosaccharomyces pombe).Pathogens. 2021 Jun 24;10(7):804. doi: 10.3390/pathogens10070804. Pathogens. 2021. PMID: 34202872 Free PMC article.
-
A fission yeast cell-based system for multidrug resistant HIV-1 proteases.Cell Biosci. 2017 Jan 11;7:5. doi: 10.1186/s13578-016-0131-5. eCollection 2017. Cell Biosci. 2017. PMID: 28096973 Free PMC article.
-
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.Acc Chem Res. 2008 Jan;41(1):78-86. doi: 10.1021/ar7001232. Epub 2007 Aug 28. Acc Chem Res. 2008. PMID: 17722874 Review.
-
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.Antivir Ther. 2001 Dec;6(4):201-29. Antivir Ther. 2001. PMID: 11878403 Review.
Cited by
-
Cellular Targets of HIV-1 Protease: Just the Tip of the Iceberg?Viruses. 2023 Mar 9;15(3):712. doi: 10.3390/v15030712. Viruses. 2023. PMID: 36992421 Free PMC article. Review.
-
SARS-CoV-2 ORF3a Protein as a Therapeutic Target against COVID-19 and Long-Term Post-Infection Effects.Pathogens. 2024 Jan 14;13(1):75. doi: 10.3390/pathogens13010075. Pathogens. 2024. PMID: 38251382 Free PMC article. Review.
-
Cleavage of TANK-Binding Kinase 1 by HIV-1 Protease Triggers Viral Innate Immune Evasion.Front Microbiol. 2021 Apr 27;12:643407. doi: 10.3389/fmicb.2021.643407. eCollection 2021. Front Microbiol. 2021. PMID: 33986734 Free PMC article.
-
Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.Viruses. 2014 Aug 19;6(8):3181-227. doi: 10.3390/v6083181. Viruses. 2014. PMID: 25196285 Free PMC article. Review.
-
Chemoselective Caging of Carboxyl Groups for On-Demand Protein Activation with Small Molecules.Angew Chem Int Ed Engl. 2023 May 22;62(22):e202215614. doi: 10.1002/anie.202215614. Epub 2023 Apr 25. Angew Chem Int Ed Engl. 2023. PMID: 36964973 Free PMC article.
References
-
- WHO. Progress Report 2011. World Health Organization (WHO), Geneva, Switzerland; 2011. Global HIV/AIDS Response: Epidemic update and health sector progress towards Universal Access; pp. 1–224.
-
- Logsdon BC, Vickrey JF, Martin P, Proteasa G, Koepke JI, Terlecky SR, Wawrzak Z, Winters MA, Merigan TC, Kovari LC. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J Virol. 2004;78:3123–3132. doi: 10.1128/JVI.78.6.3123-3132.2004. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials